November 16, 2023 1:36 AM
U.S. Food and Drug Administration’s reviewers on Wednesday flagged concerns that data on Merck’s chronic cough drug might not be sufficient to prove meaningful benefit, according to documents released ahead of the agency advisers’ meeting this week. REUTERS